Oric Pharmaceuticals Inc ORIC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
8.99UNCH (UNCH)
Volume
12,524
Close
8.99quote price arrow down-0.51 (-5.37%)
Volume
230,009
52 week range
4.91 - 16.65
Loading...
  • Open9.87
  • Day High9.87
  • Day Low8.87
  • Prev Close9.50
  • 52 Week High16.65
  • 52 Week High Date03/06/24
  • 52 Week Low4.91
  • 52 Week Low Date05/31/23

Key Stats

  • Market Cap606.127M
  • Shares Out67.42M
  • 10 Day Average Volume0.46M
  • Dividend-
  • Dividend Yield-
  • Beta1.19
  • YTD % Change-2.28

KEY STATS

  • Open9.87
  • Day High9.87
  • Day Low8.87
  • Prev Close9.50
  • 52 Week High16.65
  • 52 Week High Date03/06/24
  • 52 Week Low4.91
  • 52 Week Low Date05/31/23
  • Market Cap606.127M
  • Shares Out67.42M
  • 10 Day Average Volume0.46M
  • Dividend-
  • Dividend Yield-
  • Beta1.19
  • YTD % Change-2.28

RATIOS/PROFITABILITY

  • EPS (TTM)-1.81
  • P/E (TTM)-4.97
  • Fwd P/E (NTM)-5.16
  • EBITDA (TTM)-113.052M
  • ROE (TTM)-38.30%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Oric Pharmaceuticals Inc

 

Profile

MORE
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant...
Richard Heyman Ph.D.
Independent Chairman of the Board
Jacob Chacko M.D.
President, Chief Executive Officer, Director
Dominic Piscitelli CPA
Chief Financial Officer
Address
240 E. Grand Ave, 2nd Floor
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
SVRA
Savara Inc
4.66-0.42-8.19%
MLYS
Mineralys Therapeutics Inc
13.52-0.75-5.26%
PRME
Prime Medicine Inc
5.61-0.11-1.92%
HLVX
Hillevax Inc
13.84-0.15-1.07%
GHRS
GH Research PLC
12.81+0.82+6.84%